Glaukos Corp., an ophthalmic pharmaceutical and medical technology company, broke ground Thursday on a research and manufacturing campus in Huntsville.
The campus, in Cummings Research Park, will focus on therapies for treating glaucoma, corneal disorders and retinal diseases.
Investment in the project will be more than $80 million, the company says.
“We are proud to expand our U.S. footprint with the development of this new state-of-the-art facility to augment our current infrastructure and support our long-term growth plans, underscoring our commitment to American manufacturing and the critical role it plays in advancing healthcare innovation,” said Thomas Burns, Glaukos chairman and chief executive officer. “After evaluating over 100 potential sites worldwide, we ultimately chose Huntsville for its strong talent base and vibrant business climate.”
Glaukos’ campus will include a 200,000-square-foot facility to be built on 25 acres with the option of 15 acres for future expansion.
“For decades, Huntsville has worked to build an environment where science, technology and advanced manufacturing thrive together in a community that knows how to support discovery,” Huntsville Mayor Tommy Battle said. “Glaukos’ decision to grow here builds on that foundation, showing how our community’s strengths attract companies that are shaping the future of human health around the world.”
Glaukos is based in Aliso Viejo, California.
